ALKEM vs INDOCO: Stock Comparison

ALKEM LABORATORIES vs INDOCO REMEDIESUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

ALKEM LABORATORIES is the larger company by market capitalisation. ALKEM LABORATORIES shows a lower P/E, a higher ROE and a higher dividend yield, while INDOCO REMEDIES shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

ALKEM leads 9; INDOCO leads 4 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

ALKEMINDOCO

Valuation lens

What price are you paying?

Market CapContext only
₹62,011 Cr
₹2,421 Cr
P/E RatioALKEM has the lower reading
28.87x
445.9x
P/B RatioINDOCO has the lower reading
4.51x
2.67x
EPSALKEM has the higher reading
₹47.67
₹7.04
Book ValueContext only
₹1,200.09
₹100.98
Dividend YieldALKEM has the higher reading
1.02%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
ALKEM is the larger company
₹62,011 Cr vs ₹2,421 Cr
P/E Ratio
ALKEM has a lower P/E
28.87x vs 445.9x
P/B Ratio
INDOCO has a lower P/B
2.67x vs 4.51x
EPS
ALKEM has higher earnings per share
₹47.67 vs ₹7.04
Dividend Yield
ALKEM has a higher dividend yield
1.02% vs 0%
Revenue Growth (TTM YoY)
INDOCO has faster revenue growth
21.9% vs 14.6%
EPS Growth (TTM YoY)
INDOCO has faster EPS growth
0% vs -22.7%
Qtr Sales Growth
INDOCO has stronger quarterly sales growth
14.31% vs -28.67%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricALKEMINDOCO
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricALKEMINDOCO
Live Price₹5,190₹262.51
Day Change-0.06%-3.69%
Volume63,2613.69 L
52-Week High₹5,933.5₹332.2
52-Week Low₹5,075₹162.19
Distance from 52W High-12.53%-20.98%

Valuation

MetricALKEMINDOCO
Market Cap₹62,011 Cr₹2,421 Cr
P/E Ratio28.87x445.9x
P/B Ratio4.51x2.67x
EPS₹47.67₹7.04
Book Value₹1,200.09₹100.98
Dividend Yield1.02%0%

Growth

MetricALKEMINDOCO
Revenue Growth (TTM YoY)14.6%21.9%
EPS Growth (TTM YoY)-22.7%0%
Qtr Sales Growth-28.67%14.31%
Qtr Profit Growth9.41%-20.51%

Profitability & Leverage

MetricALKEMINDOCO
ROE16.39%-0.51%
ROCE11.48%4.26%
Net Margin15.65%-5.31%
Operating Margin20.61%4.57%
Debt to Equity0.11x0.64x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricALKEMINDOCO
Promoter Holding49.7% 1.5 pp58.86%
FII Holding10.42% 0.26 pp1.27% 0.33 pp
DII Holding22.63% 1.23 pp17.68% 0.47 pp
Public Holding17.25%22.04% 0.14 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ALKEM LABORATORIES and INDOCO REMEDIES.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.